All In Biotech

Drug Trial Radar · NCT01825031

Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy

Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy: a Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,805 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,805

Actual

Start

Jun 2013

Primary completion

Mar 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Anna Griffiths, MRCGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Department for International Development, United Kingdom; Wellcome Trust; Medical Research Council; PENTA Foundation
First posted
Apr 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomised controlled trial to investigate three methods to reduce early mortality in adults, adolescents and children aged 5 years or older starting antiretroviral therapy (ART) with severe immuno-deficiency. The three methods are: (i) increasing the potency of ART with a 12 week induction period using 4 antiretroviral drugs from 3 classes (ii) augmented prophylaxis against opportunistic/bacterial infections and helminths for 12 weeks (iii) macronutrient intervention using ready-to-use supplementary food for 12 weeks.

Conditions

  • Human Immunodeficiency Virus

Interventions

  • RaltegravirDrug

    400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs

  • FluconazoleDrug

    100mg once daily for 12 weeks

  • AzithromycinDrug

    500mg once daily for 5 days

  • AlbendazoleDrug

    a single dose 400mg

  • IsoniazidDrug

    300mg taken immediately in combination with cotrimoxazole

  • Ready to Use Supplementary FoodDietary supplement

    2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality over the first 24 weeks after starting ARTTime frame: Week 24

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Moi University Clinical Research Centre

    Eldoret, Kenya

  • KEMRI Wellcome Trust Research Programme

    Kilifi, Kenya

  • University of Malawi

    Blantyre, Malawi

  • Joint Clinical Research Centre, Fort Portal

    Fort Portal, Uganda

  • Joint Clinical Research Centre, Gulu

    Gulu, Uganda

  • Joint Clinical Research Centre, Mbale

    Mbale, Uganda

  • Joint Clinical Research Centre, Mbarara

    Mbarara, Uganda

  • University of Zimbabwe Clinical Research Centre

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.